

Tobias Gutting

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2760834/publications.pdf>

Version: 2024-02-01

14
papers

216
citations

1040056

9
h-index

1125743

13
g-index

15
all docs

15
docs citations

15
times ranked

413
citing authors

#	ARTICLE	IF	CITATIONS
1	Checkpoints and beyond – Immunotherapy in colorectal cancer. <i>Seminars in Cancer Biology</i> , 2019, 55, 78-89.	9.6	38
2	Spatial Distribution of Endogenous Tissue Protease Activity in Gastric Carcinoma Mapped by MALDI Mass Spectrometry Imaging. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 151-161.	3.8	26
3	A multicenter phase 4 geriatric assessment directed trial to evaluate gemcitabine + nab-paclitaxel in elderly pancreatic cancer patients (GrantPax). <i>BMC Cancer</i> , 2018, 18, 747.	2.6	24
4	Myotubularin-related protein 7 inhibits insulin signaling in colorectal cancer. <i>Oncotarget</i> , 2016, 7, 50490-50506.	1.8	21
5	A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA). <i>BMC Cancer</i> , 2019, 19, 231.	2.6	19
6	Subcellular compartmentalization of docking protein-1 contributes to progression in colorectal cancer. <i>EBioMedicine</i> , 2016, 8, 159-172.	6.1	15
7	PPAR δ induces PD-L1 expression in MSS+ colorectal cancer cells. <i>OncolImmunology</i> , 2021, 10, 1906500.	4.6	15
8	Docking protein-1 promotes inflammatory macrophage signaling in gastric cancer. <i>OncolImmunology</i> , 2019, 8, e1649961.	4.6	14
9	PPAR δ -activation increases intestinal M1 macrophages and mitigates formation of serrated adenomas in mutant <i>KRAS</i> mice. <i>OncolImmunology</i> , 2018, 7, e1423168.	4.6	12
10	Detection of mutational patterns in cell-free DNA of colorectal cancer by custom amplicon sequencing. <i>Molecular Oncology</i> , 2019, 13, 1669-1683.	4.6	8
11	Myotubularin-related protein 7 activates peroxisome proliferator-activated receptor-gamma. <i>Oncogenesis</i> , 2020, 9, 59.	4.9	6
12	Epigenetic silencing of tumor suppressor candidate 3 confers adverse prognosis in early colorectal cancer. <i>Oncotarget</i> , 2017, 8, 84714-84728.	1.8	5
13	Complete Remission of Metastatic HER2+ Oesophagogastric Junctional Adenocarcinoma under long-term Trastuzumab Treatment. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 28, 503-507.	0.9	2
14	Nivolumab plus ipilimumab in second-line combination therapy for older patients with esophageal squamous cell cancer (AIO-STO-0117 trial).. <i>Journal of Clinical Oncology</i> , 2022, 40, 303-303.	1.6	1